Mechanisms and Drug Intervention for Doxorubicin-Induced Cardiotoxicity Based on Mitochondrial Bioenergetics

被引:0
|
作者
Ling, Guanjing [1 ]
Wang, Xiaoping [1 ]
Tan, Nannan [1 ]
Cao, Jing [1 ]
Li, Weili [2 ]
Zhang, Yawen [1 ]
Jiang, Jinchi [1 ]
Sun, Qianbin [2 ]
Jiang, Yanyan [2 ]
Wang, Wei [1 ,3 ,4 ,5 ]
Wang, Yong [1 ,2 ,3 ,4 ]
机构
[1] School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,100029, China
[2] School of Life Sciences, Beijing University of Chinese Medicine, Beijing,100029, China
[3] Beijing Key Laboratory of TCM Syndrome and Formula, Beijing,100029, China
[4] Key Laboratory of Beijing University of Chinese Medicine, Ministry of Education, Beijing,100029, China
[5] Guangzhou University of Chinese Medicine, Guangzhou,510006, China
关键词
Biochemistry - Diseases - Drug products - Mitochondria;
D O I
暂无
中图分类号
学科分类号
摘要
Doxorubicin (DOX) is an anthracycline chemotherapy drug, which is indispensable in antitumor therapy. However, its subsequent induction of cardiovascular disease (CVD) has become the primary cause of mortality in cancer survivors. Accumulating evidence has demonstrated that cardiac mitochondrial bioenergetics changes have become a significant marker for doxorubicin-induced cardiotoxicity (DIC). Here, we mainly summarize the related mechanisms of DOX-induced cardiac mitochondrial bioenergetics disorders reported in recent years, including mitochondrial substrate metabolism, the mitochondrial respiratory chain, myocardial ATP storage and utilization, and other mechanisms affecting mitochondrial bioenergetics. In addition, intervention for DOX-induced cardiac mitochondrial bioenergetics disorders using chemical drugs and traditional herbal medicine is also summarized, which will provide a comprehensive process to study and develop more appropriate therapeutic strategies for DIC. © 2022 Guanjing Ling et al.
引用
收藏
相关论文
共 50 条
  • [41] Empagliflozin attenuates doxorubicin-induced cardiotoxicity
    Baris, Veysel Ozgur
    Dincsoy, Adnan Berk
    Gedikli, Esra
    Zirh, Selim
    Muftuoglu, Sevda
    Erdem, Aysen
    TOXICOLOGY RESEARCH, 2023, 12 (05) : 998 - 998
  • [42] Prevention of doxorubicin-induced cardiotoxicity by melatonin
    Öz, E
    Erbas, D
    Sürücü, HS
    Düzgün, E
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2006, 282 (1-2) : 31 - 37
  • [43] The Role of Neutrophils in Doxorubicin-induced Cardiotoxicity
    Bhagat, Anchit
    Kleinerman, Eugenie
    Kleinerman, Eugenie
    CIRCULATION RESEARCH, 2020, 127
  • [44] Cardiomyocyte death in doxorubicin-induced cardiotoxicity
    Zhang, Yi-Wei
    Shi, Jianjian
    Li, Yuan-Jian
    Wei, Lei
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2009, 57 (06) : 435 - 445
  • [45] Transcriptional analysis of doxorubicin-induced cardiotoxicity
    Yi, XM
    Bekeredjian, R
    DeFilippis, NJ
    Siddiquee, Z
    Fernandez, E
    Shohet, RV
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (03): : H1098 - H1102
  • [46] Prevention of doxorubicin-induced cardiotoxicity by benfotiamine
    Taylor, Justin R.
    Harames, Kyra
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Myofilament changes in doxorubicin-induced cardiotoxicity
    Goncalves Rodrigues, P.
    Miranda-Silva, D.
    Barros, C.
    Hamdani, N.
    Linke, W.
    Leite-Moreira, A. F.
    Falcao-Pires, I.
    EUROPEAN HEART JOURNAL, 2015, 36 : 897 - 897
  • [48] THE ROLE OF AUTOPHAGY IN DOXORUBICIN-INDUCED CARDIOTOXICITY
    Coleman, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2011, 59 (02) : 479 - 479
  • [49] Doxorubicin-induced apoptosis: Implications in cardiotoxicity
    B. Kalyanaraman
    Joy Joseph
    Shashi Kalivendi
    Suwei Wang
    Eugene Konorev
    Srigiridhar Kotamraju
    Molecular and Cellular Biochemistry, 2002, 234-235 : 119 - 124
  • [50] Fighting doxorubicin-induced cardiotoxicity with adiponectin
    McTiernan, Charles F.
    CARDIOVASCULAR RESEARCH, 2011, 89 (02) : 262 - 264